Your session is about to expire
← Back to Search
Unknown
QLS-101 for Ocular Hypertension
Phase 2
Waitlist Available
Research Sponsored by Qlaris Bio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 100 days
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new eye drop (QLS-101) against an existing one (timolol maleate) in patients with high eye pressure due to glaucoma or ocular hypertension. The goal is to determine if the new treatment is safe and effective in lowering eye pressure. Timolol maleate has been used for almost two decades to treat glaucoma and ocular hypertension, showing significant efficacy in reducing eye pressure.
Eligible Conditions
- Ocular Hypertension
- Glaucoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 100 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~100 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Ocular safety
Secondary study objectives
Ocular hypotensive efficacy
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Active Control
Group I: QLS-101 2%Experimental Treatment1 Intervention
Group II: QLS-101 1%Experimental Treatment1 Intervention
Group III: QLS-101 0.5%Experimental Treatment1 Intervention
Group IV: Timolol Maleate 0.5% preservative free ophthalmic solutionActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
QLS-101
2021
Completed Phase 2
~120
Find a Location
Who is running the clinical trial?
Qlaris Bio, Inc.Lead Sponsor
6 Previous Clinical Trials
203 Total Patients Enrolled
4 Trials studying Ocular Hypertension
113 Patients Enrolled for Ocular Hypertension
Share this study with friends
Copy Link
Messenger